Inmune Bio
NASDAQ: INMBLa Jolla, US · Founded 2015 · Nevada corporation
Find your way into Inmune Bio
126 people in our graph share verified history with the Inmune Bio team — schools, employers, funds. One of them is your warm intro.
Ann Crady Weissunlockedknows David J. Moss · together at UC San Diego (overlapped)
×6knows the team · via UC San Diego
×5knows the team · via Rice Business
INmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Founders & leadership
Inmune Bio was founded in 2015 by Mark Lowdell, Raymond Tesi, and David J. Moss.
ML
Mark LowdellinCSO and Co-Founder
RT
Raymond TesiChief Executive Officer
DJ
David J. MossinCEOCEO of INmune Bio, a clinical-stage biotechnology company developing immunotherapies for neurodegenerative and psychiatric diseases.
JK
J. Kelly GanjeiNamed on SEC filing
TR
Terry R. KnappNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$8M disclosed across 2 rounds · 2017–2019
▶$4.7MraisedMay 2019 · 5 investors · BiotechnologyRule 506(b)
▶$4.7MraisedMay 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raymond J. TesiExecutive Officer, Director
- David MossExecutive Officer
- Mark LowdellExecutive Officer
- J. Kelly GanjeiDirector
- Timothy SchroederDirector
- David SzymkowskiDirector
- Scott JudaDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Apr 2019
- Incorporated
- Corporation, Nevada, 2015
- Federal exemptions
- 06b
▶$3.3MraisedJul 2017 · 29 investors · BiotechnologyRule 506(b)
▶$3.3MraisedJul 2017 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark LowdellExecutive Officer, Director
- J. Kelly GanjeiDirector
- David J. MossExecutive Officer, Director
- Raymond TesiExecutive Officer, Director
- Terry R. KnappDirector
- Offering amount
- $5M
- Amount sold
- $3.3M
- Minimum investment
- $10K
- Sales commissions
- $47.5K
- Placement agents
- Westpark Capital, Inc.
- First sale
- Mar 2017
- Incorporated
- Corporation, Nevada, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Inimmune55 shared keywordsInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Immunome30 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Seeking Alpha29 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Immuneering29 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immunai28 shared keywordsImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Infinimmune28 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Companies competing with Inmune Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Inmune Bio do?
- INmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
- Who founded Inmune Bio?
- Inmune Bio was founded by Mark Lowdell, Raymond Tesi, David J. Moss in 2015.
- How much funding has Inmune Bio raised?
- Inmune Bio has disclosed $8M raised across 2 rounds.
- Where is Inmune Bio headquartered?
- Inmune Bio is headquartered in La Jolla, US.